XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.48

-1.9%

Nov 4 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (10654)	7/7/1999 8:06:00 PM
From: Pseudo Biologist	Read Replies (2) of 17367

Re <<Am I reading too much into this?>> Probably yes. Each group has chosen to release, by whatever means, information selectively. The investigators involved probably look forward to get their nice publications in the New England Journal, the Lancet, or Nature Medicine, and they do not want to let the cat completely out of the bag. But George could tell you that too. -g- But if you want to keep worrying, here is "a" list of other molecules in phase II or I/II for psoriasis: Ligands's *retins, and Ontak. Abgenix anti-IL8 human antibody ICOS's anti-ICAM-3 antibody Vertex small molecule inhibitor of T-cell proliferation Axys tryptase small molecule inhibitor IDEC's anti-B7 and (maybe??) anti-CD4 antibodies ... And here is an article from Bristol-Myers Squibb on their phase I: jci.org (some nasty pictures, so don't do after meals -g-) And this is the release on Olux phase III data (this is not directly comparable to the BGEN or XOMA trial; just another data point): connetics.com PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next